News

24. April 2017

Geistlich Pharma posts excellent 2016 results

Geistlich Pharma AG’s results for 2016 were excellent. All the subsidiaries and regions reported positive growth, which contributed to a double-digit increase in turnover overall.

Global market leader in regenerative dental medicine Geistlich Pharma successfully withstood the impact of the Swiss Central Bank’s unpegging of the CHF-euro exchange rate in 2015 and can look back on an extremely successful 2016. Geistlich Pharma more than met its growth targets for the reporting year and ended the year with a double-digit increase in turnover. The individual business units’ services also played their part. Once again the Biomaterials business unit, with its world-beating regenerative dental medicine products, made a particular contribution to growth. From a regional viewpoint the majority of the European countries also gained. There is still a positive trend to the Asia-Pacific region’s potential for growth, led by China and North America. Geistlich Pharma expanded the membrane family by another member with the launch of Geistlich Bio-Gide® Compressed. The Surgery business unit showed a double-digit improvement on the previous year’s result, mainly thanks to the German and Brazilian subsidiaries and distributors in Turkish, Russian and Spanish markets. The Medical business unit showed a slight improvement on last year’s turnover. Geistlich TauroSept® and Kelosoft® sales continue to exhibit growth in double figures compared to the previous year.

 

Assuming the role of a dynamic driver

Geistlich Pharma’s positive trend can be ascribed to its expanded global presence. In 2016 the company established its tenth subsidiary, in India. It was opened in New Delhi on 8 October 2016 in the presence of the Swiss ambassador to India, Dr. Andreas Baum. It will help the world’s leading provider of regenerative dental medicine, Geistlich Biomaterials, to penetrate a highly promising market. The company is convinced that there are prospects for long-term growth in the Indian dental market and the company can also assume the role of a dynamic driver in development of the Indian market.

The continuous growth in sales figures have caused Geistlich Pharma to introduce a new shift model in clean room production. Since November 2016 the company has been manufacturing using a classic two-shift model, to further expand the capacity which will be required long term.

 

Successful anniversary year

2016 saw the end of a very special year for Geistlich Pharma’s dental division. There were three anniversaries for Geistlich Pharma and its global partners to celebrate - 20 years of Geistlich Bio-Gide®, 30 years of Geistlich Bio-Oss® and 1,000 studies1 of Geistlich’s biomaterials.  Looking back, some of the many highlights include the Geistlich Jubilee Webinar World Tour, with five live webinars from four continents, the accolade of 15 outstanding studies using Geistlich biomaterials and the anniversary website, to which more than 2,000 dentists worldwide uploaded their publications regarding Geistlich biomaterials under the heading “Sharing Success”. Geistlich Pharma created a link to the previous year’s success with six webinars and the www.geistlich-key2success.com micro site. The portal gives dental surgeons the opportunity to upload their own publications, clinical cases or personal commentaries which highlight the success of Geistlich biomaterials.

 

1 More Information: https://www.geistlich-pharma.com/en/about-us/newsroom/dental-news/news-details/news/a-special-year-and-special-thanks/